183 related articles for article (PubMed ID: 33373589)
41. Identification of predictive factors for early relapse in patients with unresectable stage III non-small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy.
Nam JH; Yeo CD; Park CK; Kim SK; Kim JS; Kim YH; Kim JW; Kim SJ; Lee SH; Kang HS
Thorac Cancer; 2023 Sep; 14(26):2657-2664. PubMed ID: 37519059
[TBL] [Abstract][Full Text] [Related]
42. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
[TBL] [Abstract][Full Text] [Related]
43. Profiles, diagnostic process, and patterns of care of patients with stage III non-small cell lung cancer: A French national study.
Auliac JB; Greillier L; Martin E; Falcoz PE; Boisselier P; Ano S; Lefrançois M; Cortot A
Respir Med Res; 2024 Jun; 85():101087. PubMed ID: 38657298
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
45. Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report.
Yorozuya T; Taya T; Yasuda K; Nagano Y; Shioya M; Chiba H; Takahashi H
Thorac Cancer; 2020 Apr; 11(4):1090-1093. PubMed ID: 32045109
[TBL] [Abstract][Full Text] [Related]
46. Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer.
Edwards DM; Sankar K; Alseri A; Jiang R; Schipper M; Miller S; Dess K; Strohbehn GW; Elliott DA; Moghanaki D; Ramnath N; Green MD; Bryant AK
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(4):963-970. PubMed ID: 37793573
[TBL] [Abstract][Full Text] [Related]
47. The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy.
Mutlu H; Arslan D; Gündüz Ş; Tural D; Büyükçelik A; Benderli Cihan Y; Aslan T; Bozcuk H; Şenol Coşkun H
Chemotherapy; 2014; 60(2):107-111. PubMed ID: 25721008
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC.
Hussain S; Klugarova J; Klugar M
Lung Cancer; 2022 Aug; 170():11-19. PubMed ID: 35691134
[TBL] [Abstract][Full Text] [Related]
49. Salvage Surgery After Chemotherapy or Chemoradiotherapy for Initially Unresectable Lung Carcinoma.
Sonobe M; Yutaka Y; Nakajima D; Hamaji M; Menju T; Ohsumi A; Chen-Yoshikawa TF; Sato T; Date H
Ann Thorac Surg; 2019 Dec; 108(6):1664-1670. PubMed ID: 31445048
[TBL] [Abstract][Full Text] [Related]
50. Safety and efficacy of salvage surgery for non-small cell lung cancer: a retrospective study of 46 patients from four Keio-affiliated hospitals.
Suzuki S; Asakura K; Okui M; Sawafuji M; Shigenobu T; Tajima A; Kaseda K; Masai K; Hishida T; Asamura H
Gen Thorac Cardiovasc Surg; 2022 Oct; 70(10):891-899. PubMed ID: 35344124
[TBL] [Abstract][Full Text] [Related]
51. Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients.
Hosoya K; Fujimoto D; Kawachi H; Sato Y; Kogo M; Nagata K; Nakagawa A; Tachikawa R; Hiraoka S; Kokubo M; Tomii K
Cancer Chemother Pharmacol; 2019 Aug; 84(2):275-280. PubMed ID: 31201490
[TBL] [Abstract][Full Text] [Related]
52. Eight cases of salvage pulmonary resection for residual disease or isolated local recurrence detected after definitive chemoradiotherapy for N2 Stage-IIIA lung cancer.
Sawada S; Suehisa H; Ueno T; Yamashita M
Asian J Surg; 2017 Apr; 40(2):95-99. PubMed ID: 26362070
[TBL] [Abstract][Full Text] [Related]
53. Role of immunotherapy in stage III nonsmall cell lung cancer.
Wrona A
Curr Opin Oncol; 2019 Jan; 31(1):18-23. PubMed ID: 30489337
[TBL] [Abstract][Full Text] [Related]
54. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.
Flentje M; Huber RM; Engel-Riedel W; Andreas S; Kollmeier J; Staar S; Dickgreber N; Vaissiere N; De Almeida C; Edlich B; Fietkau R
Strahlenther Onkol; 2016 Apr; 192(4):216-22. PubMed ID: 26809652
[TBL] [Abstract][Full Text] [Related]
55. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
56. Assessment of recurrence of non-small cell lung cancer after therapy using CT and Integrated PET/CT.
Opoka L; Szołkowska M; Podgajny Z; Kunikowska J; Barańska I; Błasińska-Przerwa K; Jakubowska L; Rudziński P; Bestry I; Roszkowski-Śliż K
Pneumonol Alergol Pol; 2013; 81(3):214-20. PubMed ID: 23609428
[TBL] [Abstract][Full Text] [Related]
57. Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function.
Dickhoff C; Hartemink KJ; van de Ven PM; van Reij EJ; Senan S; Paul MA; Smit EF; Dahele M
Lung Cancer; 2014 Aug; 85(2):218-23. PubMed ID: 24976333
[TBL] [Abstract][Full Text] [Related]
58. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.
Tanaka F; Yokomise H; Soejima T; Uramoto H; Yamanaka T; Nakagawa K; Yamamoto N; Nishimura Y; Niwa H; Okada M; Nakagawa T; Yamashita M
Ann Thorac Surg; 2018 Oct; 106(4):1018-1024. PubMed ID: 29890150
[TBL] [Abstract][Full Text] [Related]
59. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD
JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865
[TBL] [Abstract][Full Text] [Related]
60. Early tumor shrinkage served as a prognostic factor for patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
Wei M; Ye Q; Wang X; Wang M; Hu Y; Yang Y; Yang J; Cai J
Medicine (Baltimore); 2018 May; 97(19):e0632. PubMed ID: 29742701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
